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Fetal Tissue Transplants as Treatment for 
Parkinsonian Patients: A Miracle Cure or 
Science Fiction Nightmare? 
An old film portrays the story of a woman who had been 
severely injured in an automobile accident. A scientist, motivat-
ed by his love for the injured woman and his desire to simulta-
neously further science, took the woman's decapitated head and 
miraculously preserved it so that it functioned perfectly in a 
fluid-filled tray. 
The rest of the woman's body was combined with remnants 
of other victims to make a "person". The "person" turned out to 
be a mindless monster capable only of destruction. The unfortu-
nate head, while totally capable of reason and fully apprecia-
tive of what her scientist fiance had done, wanted only to be 
allowed to die. 
Today, the movie is science fiction. But what about tomor-
row? 
I. INTRODUCTION 
In March 1992, the House of Representatives passed and 
sent the Public Health Service Act to the Senate. This bill 
proposed to remove the moratorium placed on the National 
Institute of Health which prohibited the federal funding of 
research on fetal tissue obtained from induced abortions. 1 
"Fetal" means in utero from three months until birth.2 
"Tissue" means a collection of similar cells.3 Fetal tissue comes 
from aborted fetuses. Many questions arise about these aborted 
fetuses. Are parents asked if their aborted fetuses can be dis-
sected? Do parents get paid for "goods" thus obtained? Is there 
a "market" for fetal tissue? How does this relate to the abortion 
issue? 
What should an anti-abortion person think about this pro-
cedure? Can one justify elective abortion if it will alleviate a 
1 The bill ultimately did not pass. President Bush would not sign it, and 
Congress did not have the votes to override his veto. See infra part IV.A. 
2 ILLUSTRATED STEDMAN'S MEDICAL DICTIONARY 521 (5th ed. 1982) (see "fe-
tus"). 
3 ld. at 1456. 
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living person's inevitable physical and mental anguish? Some 
Christian beliefs suggest "no."4 The following is the result of 
my struggle to shed light on a personally clouded issue.5 
This article will review the etiology of Parkinson's Disease. 
It will review the effectiveness of traditional Parkinson's Dis-
ease therapy and discuss the current areas being researched. It 
will then analyze the arguments for and against the use of 
fetal tissue research, in general, in relation to the moratorium; 
and in treating Parkinson's Disease specifically. It will addi-
tionally demonstrate the availability of alternative areas of 
research for treatment of Parkinson's Disease. Finally, the 
Clinton Administration's policy on the use of fetal tissue will be 
discussed. 
II. PARKINSON'S DISEASE 
A. The Nature of Parkinson's Disease. 
Parkinson's Disease (PD) is a chronic, progressive illness.6 
The actual cause of the disease is unknown. 7 In fact, the pro-
cess of elimination is used more in PD diagnosis than in the 
diagnosis of almost any other disease.8 
What physicians do know is that PD patients have a defi-
ciency of special brain cells which produce a chemical called 
dopamine. 9 Dopamine aids the passage of stimuli and respons-
es to and from the brain. 10 Without this chemical, neural 
transmissions are terminated or impaired, causing the typical 
PD patient to have uncontrollable tremors of the limbs or the 
head; a loss of balance; a temporary, involuntary inability to 
4 "For a good tree bringeth not forth corrupt fruit; neither doth a corrupt 
tree bring forth good fruit." Luke 6:43. 
5 My mother, Liddy Bankston Baird, was diagnosed with Parkinson's Dis-
ease in March of 1992. This article is dedicated to her. 
6 A.N. Lieberman et a!., Parkinson's Disease Handbook: A Guide for Pa-
tients and Their Families. 
7 ld. at 2. 
8 ld. at 2, 11-13. 
9 This deficiency is caused by the death of these specialized cells. What 
causes this cellular death is unknown though current speculations include genetic 
susceptibility; environmental toxins (see William C. Scott & Russell H. Patterson, 
Council on Scientific Affairs and Council on Ethical and Judicial Affairs, Medical 
Applications o( Fetal Tissue Transplant, 263 JAMA 565 (1990)); human chemical 
production abnormalities; and viral infections. It is known that many victims of a 
world wide epidemic of viral encephalitis (between 1918 and 1932) developed PD. 
10 Lieberman et a!., supra note 6, at 3. 
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move; a poor or stooped posture; and/or a slow, shuffling step 
when walking. 11 The level of incapacity can range from mild 
interference and annoying tremor, to total, bedridden depen-
dence.12 
B. The Treatment of Parkinson's Disease 
There is presently no cure for PD.13 All treatments are 
designed to ameliorate symptoms only. 14 The most commonly 
used treatment is a progressively complex regime of medica-
tions meant to augment dopamine levels in the brain, and to 
combat the many side effects of the medications themselves. 15 
The numerous side effects along with the increasing and inevi-
table tolerance to PD medications 16 make alternate treatment 
methods desirable. 
The most recently researched treatment methods involve 
transplantation of tissue into the brain. Two different types of 
tissue have been used. The first type, used between 1987 and 
1988, was tissue taken from the PD patient's own adrenal 
gland (located above the kidneys) and transplanted into his 
brain. 17 The second type of tissue used was fetal tissue. 18 Fe-
tal tissue was (and still is) an attractive source of grafts for 
scientists because it presents fewer of the complications associ-
ated with other types of transplants. 19 
11 Other symptoms include drooling, forced eyelid closure, difficulty in swal-
lowing, incontinence, impotence, sleep disturbances, senility, dementia, and speech 
problems. Lieberman et al., supra note 6, at 5-10. 
12 Lieberman et al., :-;upra note 6, at 14 (rating scale). 
13 Lieberman et al., :-;upra note 6, at 16. 
14 !d. at 16. 
15 Levodopa (L-dopa) and L-dopa compounds are the most effective medica-
tions used to control PD symptoms. L-dopa side effects include hallucinations and 
depression. Lieberman, supra note 6, at 19. 
16 Lieberman et al., supra note 6, at 21. 
17 Enrico Fazzini, A Comparison of Neurosurgical Procedures in the Treat-
ment of Parkinson's Disease, AM. PARKINSON DISEASE Ass'N, Spring 1993, at 4. 
18 The fetal tissue used in experimentation included fetal adrenal tissue and 
fetal brain tissue. !d. 
19 David R. Liskowsky, Neural Grafting: Repairing the Brain and Spinal 
Cord, 265 JAMA 3225 (1991) (stating that an autograft (taking tissue from one 
area of the PD patient for transplant into another area) put the PD patient at risk 
of two very complex surgeries; transplants from non-fetal donors risk rejection of 
the tissue; and genetically engineered (or cloned) cells are not yet scientifically 
feasible). But see infra pp. 190-92. 
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III. FETAL TISSUE USE 
A. Foreign Fetal Tissue Transplantation in Treatment of 
Parkinson's Disease 
Because of the relative localization of the area of the brain 
damaged, PD was selected as an ideal disorder for transplant 
experimentation.20 However, since implantation of adrenal 
tissue had yielded only minimal, inconsistent and transitory 
results,21 in 1987 scientists turned their focus towards fetal 
tissue implantation.22 
Scientists have found fetal tissue easier to work with be-
cause it has the unique ability to differentiate into the cell type 
surrounding it.23 This means that when fetal tissue is im-
planted in the brain it becomes brain cells like those into which 
it was transplanted. Therefore, the likelihood of the PD 
patient's body reacting to and rejecting the transplanted tissue 
as "foreign" is lessened. 24 
Mexico's Dr. Ignacio Madrazo was one of the first to do a 
study comparing transplantation of fetal adrenal tissue with 
fetal brain tissue. 25 According to Madrazo, the adrenal trans-
plant patients showed an amelioration of rigidity of movement 
but no other improvement in symptoms.26 Drug therapy that 
was initially lowered, required gradual increasing.27 The re-
cipients of the fetal brain tissue showed an amelioration of 
more symptoms, and all were able to lessen medication lev-
els.28 
Although Madrazo called his results (after one year of 
observation) "encouraging,"29 his factual findings and the re-
sultant conclusions drawn have been questioned.30 As Sarah 
20 Scott & Patterson, supra note 9, at 569. 
21 Liskowsky, supra note 19, at 3225. 
22 Fazzini, supra note 17, at 4. 
23 Scott & Patterson, supra note 9, at 566. 
24 ld. 
25 Ignacio Madrazo et al., Fetal Homotransplants (Ventral Mesencephalon and 
Adrenal Tissue) to the Striatum of Parkinsonian Subjects, 47 ARCH. NEUROL. 1281 
(1990). 
26 ld. at 1283. 
27 ld. 
28 ld. 
29 ld. at 1284. 
30 Thomas B. Freeman & G. Warren Olanow, Fetal Homotransplants in the 
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Glazer reported in her article, The Fight over Fetal Tissue, 31 
researchers found Madrazo's "results to be exaggerated, short-
lived and accompanied by an unacceptable rate of complica-
tions."32 
In 1991 an English study was done exclusively using fetal 
brain tissue.33 Although the English results were initially 
more promising than Madrazo's, the long term effects (at the 
end of one year) once again proved inconsistent and tempo-
rary.34 
B. The Use of Fetal Tissue in the United States 
The use of fetal tissue began decades ago. In the 1950s, 
human fetal kidney cells were used in the development of the 
polio vaccine.35 Fetal thymus transplantation was also used in 
the treatment research for DiGeorge's Syndrome.36 
Since the 1950s, fetal tissue grafting research has been 
done in animals for many disorders, including the neurological 
disorders of Huntington's Disease, Alzheimer's Disease, and 
motor neuron disease. 37 Research done on animals has also 
been done on spinal cord injuries, brain disorders, epilepsy, 
diabetes, multiple sclerosis, the mechanisms of viral infections, 
the diagnosis of viral infections, and detecting markers for 
Treatment of Parkinson's Disease, 48 ARCH. NEUROL. 900 (1991). According to Free-
man, the best period for neuronal development before axonal extension is 6.5 to 8.0 
weeks gestation. All of Madrazo's fetuses were older than that. He also argued, 
among other things, that the initial improvement of the patients occurred too 
quickly to be the results of neuronal outgrowth of dopaminergic neurons. Id. at 
901. 
.31 Sarah Glazer, The FiRht over Fetal Tissue, WASH. POST, June .30, 1992, at 
Z10 . 
.32 Id . 
.3.3 Bruce T. Henderson et al., Implantation of Human Fetal Ventral Mesen-
cephalon to the Right Caudate Nucleus in Advanced Parkinson's Disease, 48 ARCH. 
NEUROL. 822 (1991) . 
.34 Id. at 825 . 
.35 Henry L. Nadler, Fetal Tissue Transplantation, 14.3 AM. J. Dis. CHILD. 
149 (1989). DiGeorge's Syndrome is a disease which develops in the embryonic 
stages of development. The pharyngeal (throat) region fails to develop into the 
thymus gland. Without the thymus, a person falls victim to multiple viral and fun-
gal infections which the person is unable to fight off due to weak production of 
lymphocytes (which destroy viruses and fungi). It is hideously disfiguring and inev-
itably fatal-usually at a very early age. See Rebecca H. Buckley, Immunodeficiency 
Diseases, 268 JAMA 2797 (1992) . 
.36 Id . 
.37 See Scott & Patterson, supra note 9, at 566; Liskowsky, supra note 19, at 
.3225. 
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inherited diseases.38 So far, only diabetes39 and Parkinson's 
Disease research have progressed to the human testing 
stage.40 
IV. PRESIDENT BUSH'S MORATORIUM ON GOVERNMENT FUND-
ING FOR RESEARCH INVOLVING ELECTIVELY ABORTED FETUSES. 
A. Beginning the Moratorium 
In March 1988, the Assistant Secretary of Health issued a 
moratorium on federal funding to the National Institute of 
Health for research on fetal tissue obtained from induced abor-
tions.41 In a letter refusing approval of the Public Health Ser-
vice Act, President Bush carefully and clearly articulated his 
stand on this issue.42 He began by reiterating that the mor-
atorium was not a ban on fetal tissue research altogether (the 
moratorium did not affect the privately funded sector); nor was 
it a ban on all federal funding of fetal tissue researchY He 
reminded the House that the moratorium only affected federal 
funding of research on tissue obtained from induced abor-
tions.44 
Funding for research using tissue obtained from spontane-
ous abortions or ectopic45 pregnancies was not affected.46 
Furthermore, he stated that quantities obtained from these 
funded sources should be sufficient for the researchers' 
needsY President Bush went on to say that the interests of 
this nation would not be served through the federal funding of 
research that was "promoting and legitimatizing abortion," and 
38 Scott & Patterson, supra note 9, at 566. 
39 George Archibald, NIH Skirts Ban on Transplants of Fetal Tissue, WASH. 
TIMES, Jan. 6, 1992, at A7 (stating that the first unsuccessful human fetal pancre-
as transplant for diabetes was performed in 1939; the first successful (reduced dai-
ly insulin by 20%) transplantation was done in 1986). 
40 Liskowsky, supra note 19, at 3225. 
41 Nadler, supra note 35. 
42 Message to the House of Representatives Returning Without Approval the 
National Institute of Health Revitalization Amendments of 1992, 28 WEEKLY COMP. 
PRES. Doc. 1132 (June 23, 1992) [Hereinafter Message to the House]. 
43 ld. 
44 ld. 
45 An ectopic pregnancy is one where the fetus grows outside the womb and 
must be surgically removed. Glazer, supra note 31. 
46 Message to the House, supra note 42. 
47 ld. 
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which is "morally repugnant" to many Americans. 48 
Many doctors presented opinions to the House and Senate 
to the effect that the moratorium imposed too heavy a restric-
tion on the potential advancement of science based on an ab-
stract possibility of swaying ambivalent mothers toward getting 
an abortion.49 They further argued that the regulations that 
would be included in the Revitalization Amendment would be 
sufficient to remove the "possibility of evils" associated with 
tissue harvesting.50 
The proposed United States regulations were quite similar 
to those of the United Kingdom and Mexico. They included 
prohibitions on purchase of fetal tissue; solicitation of tissue 
from an induced abortion when there is a specified donee and 
the donor/donee are related, or when the soliciting person gives 
valuable consideration for costs of the abortion; and altering of 
timing, method, or procedure for termination solely for obtain-
ing tissue.51 The proposed regulations also include the follow-
ing requirements: informed consent from the donor; consent to 
the abortion prior to the request for consent for tissue donation; 
full disclosure of any personal interest the physician may have 
in the tissue; researchers can have no part in timing, method 
or procedure for the abortion; and the donee must know the 
tissue received is aborted or stillborn human tissue donated for 
this purpose. 52 
As proposed, the United States' regulations would be very 
similar to those established in Mexico and Great Britain. Those 
countries specify the need for informed consent of the donor, 
obtained separately from the consent for the abortion, and in a 
method more conducive to a non-prejudiced decision to 
abort. 53 Mexico's statute in 1990 required the use of spontane-
ously aborted tissue only.54 Great Britain and the United 
States both concur that the method of abortion may not be 
altered after consent to donate the fetus has been given.55 
48 ld. 
49 138 CONG. REC. 84759 (daily ed. Apr. 2, 1992). As yet, neither side of 
this issue has generated demographics or offered any other type of factual proof to 
support their position. 
50 ld. at 4759. 
51 138 CONG. REC. H3340, at 3342 (daily ed. May 18, 1992) (reporting on 
H.R. 2507). 
52 ld. at 3342. 
53 NEURAL TRANSPLANTATION 140 (Stephen B. Dunnett & Anders B. Jorklund 
eds., 1992). 
54 Madrazo et al., supra note 25. 
55 See Code of Practice on the Use of Fetuses and Fetal Material in Research 
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This avoids putting the mother in a higher level of risk caused 
by different abortion procedures in order to retrieve usable 
tissue. 56 
Mexico's regulatio-ns are quite similar to those proposed for 
the United States except they restrict tissue to spontaneously 
aborted tissue only,57 whereas neither the United States58 
nor the United Kingdom place any restriction on the cause of 
the abortion. 59 
Dr. Jay Moskowitz, then Associate Director for Science 
Policy and Legislation at the National Institute of Health, 
argued for the removal of restrictions on electively aborted 
tissue because the use of spontaneously aborted tissue would 
net a poorer quality tissue and an insufficient number of avail-
able fetuses. He claimed: 
The cells and tissues from spontaneous abortions and ectopic 
pregnancies are generally of poor quality because they (a) 
may represent inherently abnormal tissue, (b) have been 
subjected to diminished blood supply, (c) exist in a poor in-
vivo environment, (d) may have been retained in the body for 
five to eight weeks prior to explosion [sic]. The state of disin-
tegration of these tissues is another factor affecting viabili-
ty.60 
Drs. Freeman and Olanow added that bacteria associated 
with spontaneously aborted fetuses transmitted to the fetus 
through vaginal delivery of the fetus can increase the potential 
for transplant related infections.61 
B. Establishment and Purpose of a Fetal Tissue Bank 
On May 19, 1992, President Bush, sensitive to the 
researchers' need for fetal tissue, while true to his pro-life con-
victions, ordered the establishment of a fetal tissue bank.62 
and Treatment, FFMC (from Her Majesty's Stationery Office 1989) cited in FETAL 
TISSUE TRANSPLANTS IN MEDICINE 331-32 (Robert G. Edwards ed., 1992); 138 
CONG. REC. H3340, supra note 51, at 3342. 
56 NEURAL TRANSPLANTATION 140 (Stephen B. Dunnett & Anders B. Jork!und 
eds., 1992). 
57 Madrazo et al., supra note 25. 
58 138 CONG. REC. H3340, supra note 51. 
59 Henderson et al., supra note 33. 
60 Continuing Debates About Human Fetal Tissue, 1992 BIOLA W 2503 [herein-
after Continuing Debates]. 
61 Freeman & Olanow, supra note 30, at 900. 
62 Exec. Order No. 12,806, 57 Fed. Reg. 21,589 (1992) [hereinafter Exec. 
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With the establishment of the tissue bank, President Bush 
tried to soften the impact of the moratorium by authorizing col-
lection of fetal tissue obtained through spontaneous abortions 
and ectopic pregnancies and by making this tissue available to 
qualified researchers. 63 He also authorized development of "cell 
lines" in accordance with the spontaneous abortion/ectopic 
pregnancy limitations.64 A "cell line" is the "capacity to clone, 
or endlessly reproduce, certain fetal cells in a laboratory in 
immortal ... lines."65 
C. Support for the Moratorium and a Fetal Tissue Bank 
Louis W. Sullivan, as Secretary of the Department of 
Health and Human Services, enumerated the "compelling rea-
sons" for supporting the President's establishment of a fetal 
tissue bank.66 First, adequate tissue could be collected from 
spontaneous abortions and ectopic pregnancies at six major 
medical centers across the nation. Second, the administration's 
estimate of the number of fetuses needed is a conservative one. 
"Only 60 fetal tissue transplants have been conducted in the 
last 30 years,"67 and according to the Bush estimate, 1000 us-
able fetal cadavers could be collected annually.68 Finally, the 
federal govemment already funds the National Institute of 
Health's research in the alternative research avenues (cell lines 
for one).69 
There are other reasons for banning the funding and the 
use of electively aborted tissues. One argument is that federally 
funded use of electively aborted fetuses legitimizes abortion. 
This was a signal the Bush administration did not wish to 
send. 70 
Another argument against allowing the use of elective 
abortions is that it could lead to the development of a "baby 
Order 12,806]. This was not the first time a tissue bank had been established. In 
1961 the NIH funded the Central Laboratory for Human Embryology at the Uni-
versity of Washington in Seattle. See Archibald, supra note 39, at A7. 
63 Exec. Order 12,806, supra note 62, § 2. 
64 Exec. Order 12,806, supra note 62, § 3. 
65 Rorie Sherman, The Selling of Body Parts, NAT'L L.J., Dec. 7, 1987, at 1. 
66 Louis W. Sullivan, Good Reasons for the Fetal Tissue Research Ban, 
WASH. POST, Aug. 16, 1992, at C6. 
67 ld. 
68 Julianne Byrne, On Fetal Tissue, Bush Shows He's Pro-Death; Tissue 
Bank Is Needed, N.Y. TIMES, July 14, 1992, at A24. 
69 Sullivan, supra note 66. 
70 Message to the House supra note 42. But see infra part IV.H. 
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market" and pregnancies for abortions' sake.71 Competition 
and the prospect of monetary remuneration could encourage 
doctors to use procedures with higher risk to the mother in 
order to obtain usable fetuses for research.72 
D. Arguments Against the Moratorium and the Alleged Suffi-
ciency of a Fetal Tissue Bank 
Opponents of the ban agree that use of elective abortions 
could result in a "baby market.'m They argue, however, that 
this result would not be all bad. For now, a fetus does not qual-
ify as a "baby." Like blood, a fetus is considered just a collec-
tion of cells. Sale of blood is not prohibited generally, so why 
should the sale of fetuses be prohibited?74 Opponents of the 
ban argue further that the Bush position was hypocriticaL 
They argued that there was already a "private market" for 
fetuses tacitly sanctioned by the government as long as federal 
funds were not involved. 75 
Proponents of fetal tissue research argue that any "proce-
dure" problem can be eliminated by regulations against alter-
ing the planned abortion procedure after permission to donate 
the tissue has been obtained from the mother. 76 However, 
growing interest in fetal tissue research will also increase the 
availability of commercial incentives.77 In fact, there is al-
ready a high demand for tissue collected, live "from abortions 
performed in weeks 20 through 24."78 Pro-choice proponents 
claim that second and third trimester abortions are "unusual," 
but the Centers for Disease Control estimates that about 
16,000 abortions a year are done after twenty weeks gesta-
tion. 79 Furthermore, at the Risk Management Seminar of the 
National Abortion Federation's September 1992 seminar, ten 
practitioners gave papers on performing second trimester abor-
71 See Sherman, supra note 65, at 32. 
72 NEURAL TRANSPLANTATION, supra note 53, at 140. 
73 !d. at 32. 
74 Michael Schrage, Vision and Rational Discussion Needed in Fetal Tissue 
Debate, WASH. POST, July 31, 1992, at F3. 
75 ld. See also 138 CONG. REC. S4759, supra note 49 (Senator Adams read-
ing a letter by Reverend Guy Walden into the record). 
76 138 CONG. REC. 84759, supra note 49. 
77 Douglas Turner, Ethics Issues Raised in Use of Fetal Tissue, BUFFALO 
NEWS, June 14, 1993, at 3; see also, Roger W. Evans, Organ Procurement Expen-
ditures and the Role of Financial Incentives, 269 JAMA 3113 (1993). 
78 Turner, supra note 77, at 3. 
79 !d. 
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tions.80 Dr. Martin Haskell's seminar included a procedure for 
removing brain tissue from a fetus in a manner meant to "pro-
tect the skull and its contents until the last minute."81 This 
seems an unnecessary concern unless the goal is actually ob-
taining usable fetal brain tissue. 
It is also argued that President Bush's estimate on the 
number of available fetuses, as well as the number of fetuses 
needed, was an inaccurate one. They argued that spontane-
ously aborted tissue and ectopic pregnancies are argued to be 
inherently infected or defective.82 Electively (or surgically) 
aborted fetuses are, as Dr. Bernadine Healy (then Director of 
the National Institute of Health) said, "[a]pt to be uninfected 
and more likely to be genetically normal."83 As the demand for 
fetal tissue transplants increases as progress is made, the 
bank's supplies will be inadequate to meet the demand.84 
Without federal funding many Parkinson's patients who 
desired fetal tissue transplantation would not be able to obtain 
it because of its tremendous cost. The government, under the 
moratorium, does not "foot the bill" for these experimental 
operations if electively aborted fetuses are used.85 This argu-
ment, however, is premised on the assumption that researchers 
will not be doing the operations unless electively aborted fetus-
es are provided. 
Another unpersuasive argument is that the lack of federal 
funding discourages colleges and hospitals from participating in 
fetal tissue transplant research and thereby diminishes the 
"brain pool" available for new research.86 Again, the assump-
tion is that researchers will use electively aborted fetuses or 
not research at all. 
E. Analysis of the Two Counter-Arguments 
The arguments pertaining to demand and availability of 
fetuses is unpersuasive. Future demand may increase, but until 
it does-and a great deal depends on federal funding of such 
80 !d. 
81 !d. 
82 Continumg Debates, supra note 60. 
83 James Mason, Fetal Transplant Fallacies, WASH. TIMES, June 16, 1992, at 
F3 (quoting Dr. Healy). 
84 !d. 
85 Gina Kolata, Evidence Found that Fetal Tissue Transplants Can Ease a 
Brain Disease, N.Y. TIMES, May 7, 1992, at Bll. 
86 !d. 
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research-the bank's 1000 fetuses should suffice. Even if the 
estimate of available fetuses was reduced by one-half, the .cur-
rent need for fetal tissue could be met.87 An odd contradiction 
among the pro-choice and pro-federal funding arguments 
arises. The proponents of lifting the ban claimed, as one of 
their foremost arguments, that the ban would create a deficien-
cy in available fetuses. Pro-choice advocates, who wanted the 
lifting of the ban on federally funded fetal tissue research, also 
want the ban on the French abortion pill RU 486 lifted.88 
Since RU 486 must be used before the eighth week of pregnan-
cy, and harvesting the most usable tissue generally takes place 
after the seventh week of gestation, it seems that the wide use 
of RU 486 would significantly increase the deficit of available 
fetuses claimed to be so detrimental to the advancement of 
scientific research in this area. 
The argument that some PD patients will be denied treat-
ment without federal funding (due to the moratorium) has 
more "teeth" than does the numbers argument. Five hundred 
thousand people are estimated to be suffering from PD.89 At 
least one report places this amount as high as one million peo-
ple. 90 As progress is made, if it is ever made, those desirous to 
be participants in this research will also increase. It is quite 
possible that the number of people desiring transplants could 
exceed the number of fetuses obtained through spontaneous 
abortions or ectopic pregnancies (especially since fetal tissue 
research is not only done for PD ). 
Although private funding can be used to transplant with 
an electively aborted fetus, the cost of this procedure begins at 
$30,000.91 This cost is to the patient because insurance usual-
ly does not pay for experimental procedures. Private donations 
can help, but only minimally. Dr. Eugene Redmond, neural 
transplant program director at Yale University, said that if 
federal funding were available, his program would do at least 
one PD related transplant per month in contrast to the eleven 
87 Byrne, supra note 68, at A57. 
88 Kate Michelman & Marcy Wilder, The RU 486 Dilemma; Abortion Drug 
Must Be Legal, NAT'L L.J., Sep. 7, 1992, at 13. See infra p. 193. 
89 Schrage, supra note 74. 
90 Dwight E.M. Angell & Hugh McCann, Fetal Tissue Research May Help 
Victims of Parkinson's Disease, GANNETTE NEWS SERVICE, Feb. 9, 1993; see also 
Lieberman et a!., supra note 6, at 1. 
91 Glazer, supra note 31. 
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operations done in three years on private funding. 92 The avail-
ability of this procedure to only those who can afford to pay 
"throws a tremendous bias into the system."93 However, the 
removal of the ban will not lessen the expense of the procedure, 
it will merely shift the burden of paying for it onto the taxpay-
er. Even if the procedure becomes a "standard" one, there is no 
evidence that the cost to patients or insurance companies will 
lessen. In fact, the present trend of our health care system 
demonstrates quite the reverse. Additionally, even if a national 
health care plan is adopted, this procedure is probably too 
costly and too infrequent to ever merit inclusion. 
The allegation that the moratorium on federally funded 
research (involving electively aborted fetuses) drains the "brain 
pool" of competent researchers seems clearly a misleading one. 
Although Dr. Eugene Redmond, Jr. said that "there ha[d] been 
major private foundations and drug companies that otherwise 
would have supported this research, but [didn't] because of the 
moratorium;"94 and that now "researchers will have more se-
curity than they did with private funds,"95 there are alternate 
research areas, whose funding was not, nor is it now, signifi-
cantly reduced. The media and many anti-ban proponents kept 
conveniently forgetting this fact and generally do not even 
mention alternatives to federally funded fetal tissue research. 
Paul Reiser, a professor of neurology with the University of 
Florida, said that the moratorium caused "no standstill" in fetal 
tissue research.96 Using "private funds, medical societies and 
other institutions," fetal tissue research has "flourished in doz-
ens of states" these "past 4 years.'m Actually, several authors 
raved about the "promise" and "tremendous progress" of fetal 
tissue transplantation in treating PD,98 when in reality even 
the physicians conducting the research say that fetal tissue 
transplants do not cure PD nor are they even considered a 
92 !d. 
93 Legislative and Other Developments in Human Fetal Tissue Transplanta-
tion Research, 1992 BIOLA W 2433, 2437 [hereinafter Legislative and Other Devel-
opments] (quoting Dr. Rohert Breeze). 
94 Marlene Cimons & Thomas H. Maugh, II, After Five-Year Wait, Scientists 
Are Set to Resume Research on Fetal Cells, L.A. TIMES, Jan. 26, 1993, at AS. 
9fi !d. 
96 Eric Adler, Ban on Fundinp Ff'tal Tissue Research Seldom Stopped Work, 
PHOENIX GAZJ.:TI'E, Jan. 23, 1993, at Al. 
97 !d. 
9R Kolata, supra note Rfi (quoting Dr. Olanow). 
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successful long-term treatment.99 
While some of the arguments for using electively aborted 
fetuses in research for Parkinson's are somewhat persuasive, 
ultimately the decision hinges on the diminishment of the hu-
man being to a bundle of marketable goods. 100 The Pope, in 
his 1993 Colorado speech, said we are developing "a spreading 
anti-life mentality, an attitude of hostility to life in the 
womb."101 What will opponents to the ban argue as technolo-
gy pushes back (toward conception) the age of viability for 
fetuses? Are embryos conceived outside the womb, and then 
"grown" outside the human body-maybe eventually grown to 
full term in an artificial womb (an area of research currently in 
progress)102 considered babies? At what point? Currently, 
there are no answers to these questions. 
F. General Arguments Against Fetal Tissue Use in Treating 
Parkinson's Disease 
During the congressional consideration of the Public 
Health Service Act, opponents of Bush's moratorium argued 
that to control fetal tissue research in any fashion was to sen-
tence PD patients, like Senator Udall, to unnecessary suffer-
ing. 103 Yet, none of the studies have concluded that their pro-
cedures were or were not successful. Dr. Olanow himself said 
that the transplant-treated patients "are by no means 
cured."104 
Swedish researcher Ollie Lindvall went even further. He 
said, "[a]lthough animal experimental data are very promising 
and clinical trials have given encouraging results, it must be 
underscored that there exists at present no treatment for 
99 Mason, supra note 83 (quoting Lindvall). 
100 It is quite different to use a fetus which would have died anyway, than 
to use one that is deliberately killed and then purchased. This is analogous to 
murdering someone for their kidneys. Though there are current laws on the sale of 
body parts in the United States (see infra note 117), the selling of body parts 
world-wide is not unheard of-especially in India and China. See Barbaric Trade: 
Harvesting Organs of Executed Prisoners, GAZETIE, March 30, 1993, at A2; Risks to 
Buying Kidneys, STRAITS TIMES, May 13, 1992, at 3. 
101 Martin Walker, Pope Tones Down Abortion Speech, GUARDIAN, Aug. 16, 
1993, at 6. 
102 William A. Check, Margery Shaw, MD. JD: Twice Counselor, 247 JAMA 
2R84, 2890 (1982) (quoting Dr. Shaw as saying that an artificial womb may be 
possible in the future). 
103 138 CONG. REC. S4759, supra note 49 (quoting Senator Domenici). 
104 Kalata, supra note 85. 
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Parkinson's Disease based on intracerebral transplanta-
tion."105 
As yet, there has not even been a consensus on the several 
important issues, including the brain region for implantation, 
the best surgical technique to use, the need for immunosup-
pressants, the best fetal age for harvesting tissue, the type of 
tissue to use, the clinical usefulness, or any long term re-
sults.106 Until such consensus can be made, or a definitive 
long-term benefit is attained, there seems no reason to focus 
exclusively (or extensively) on fetal tissue research, especially 
when there are alternate areas of research just as promising 
which do not require fetal tissue and therefore do not involve 
the abortion issue. 107 
It is the moral issue of abortion which generally caused 
Bush to implement the moratorium. 108 This alleged need for 
fetal brain tissue puts at issue the very concept of a fetus as 
non-living-not worth the sacrifice of a woman's privacy. One 
recent article in the ''Washington Post" even listed "spontane-
ous sex, luxury, extended travel, higher education, unbroken 
career paths, choosing a different father, and limiting family 
size" as "perks" of abortion. 109 This seems to put "creat-
ing/terminating life" right below waiting for the telephone man, 
and just above a bad haircut on the scale of "inconveniences." 
Yet, as Paul Panuli and Paul O'Connor put it, "[o]ne simply 
cannot have it both ways. The first trimester fetus cannot be 
simultaneously a 'blob' and a human being with a specialized 
brain structure suitable for transplant."110 If "human" fetal 
tissue is so superior to other mammalian tissue, m "how can 
it be denied ... that the child in the womb ... is fully 
'human' ... and entitled to full protection of the law."112 
This subordination of fetal life to what seems an increasing 
tenacity to live at all costs would combine to encourage, or at 
105 Mason, supra note 83. 
106 Curt R. Freed et al., Transplantation of Human Fetal Dopamine Cells for 
Parkinson's Disease: Results at 1 Year, 47 ARcH. NEUROL. 505 (1990). 
107 For example, cell lines, genetic engineering, alternate surgeries, new 
drugs. 
108 Message to the House, supra note 42. 
109 Carolyn Hax, No Birth, No Pangs; For Many Young Women, Abortion is a 
Given, WASH. POST, March 21, 1993, at Cl. 
110 Legislative and Other Developments, supra note 93, at 2436 (quoting Paul 
Panuli and Paul O'Connor). 
111 Turner, supra note 77. 
112 ld. 
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least justify for some, abortion. Though proponents of the Pub-
lic Health Service Act argued that their proposed regulations 
would prevent encouragement of abortion by waiting to ask for 
donation of a fetus until after the consent to abort was giv-
en, 113 they fail to consider the wide publicity associated with 
any abortion issue. Pro-Life and anti-abortion supporters air all 
the ramifications of their opponent's proposals openly to the 
press as often and as loudly as possible. It seems impossible, 
therefore, to believe that the majority of American women will 
be ignorant of the possible use of an aborted fetus for medical 
research. Waiting to ask for consent until after the abortion 
decision is made, is rather like a judge requesting the jury to 
disregard a statement made in court by a witness or counsel. 
Legally it may work, but realistically it is very hard to put 
those thoughts out of one's mind when making the final deci-
sion. 
Proponents of the use of federally-funded fetal tissue re-
search also failed to adequately respond to the challenge that 
use of electively aborted fetuses can lead to baby selling. Super-
ficially, doctors and legislators say the regulations preventing 
the donor from receiving monetary gain would sufficiently exor-
cise this particular problem 114 (if in fact it even is one). But 
donors are not the only ones susceptible to the lure of a poten-
tially lucrative market. Even now, legislatures and courts are 
faced with deciding who is entitled to monetary remuneration 
for patented "cell lines"115 and who is the "owner" of fetuses 
used in surrogacy cases. 116 Until recently, research labs and 
doctors/scientists were the only ones receiving the compensa-
tion from research done with someone else's body parts. 117 In 
fact, the growing concern over the conflicting interests of re-
searchers and commercial investors has lead to the adoption of 
113 138 CoNe;. REC. 84 759, supra note 49 (quoting Senators McCain and 
Riegle respectively). 
114 138 CONG. REC. S4759, supra note 49 (quoting Senator Dodd). 
115 Moore v. Regents of Univ. of Cal., 271 Cal. Rptr. 146 (Ct. App. 1990), 
cert. denied, 1991 U.S. LEXIS 1723 (1991). 
116 In Re Baby M1, 525 A.2d 1128 (N.J. Super. Ct. Ch. Div. 1987), rev'd, 537 
A.2d 1227 (N.J. 1988). 
117 Many states have legislation making it a crime to buy or sell human or-
gans within their jurisdictions. See, e.g., CAL. PENAL CODE § 367f (Deering 1992); 
FLA. STAT. ch. 873.01 (1991); LA. REV. STAT. ANN. § 14:101.1 (West 1992); MD. 
CODE ANN., HEALTH-GEN. § 5-408 (1991); NEV. REV. STAT. ANN. § 201.460 (Michie 
1991); S.D. CODIFIED LAWS ANN. § 34-26-44 (1992); TEX. PENAL CODE ANN. § 48.02 
(West 1992). 
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"disclosure" statements. 118 For example, some universities 
require "scientists to disclose not only who pays for their work, 
but whether they have any outside income from industrial or 
corporate sources, or any stock in companies whose products 
they test."119 Medical journals are also starting to list the fi-
nancial backers of each study, and "whether the private spon-
sor ... was involved in collecting data, analyzing it or approv-
ing the final article." 120 
Finally, there is a strong presumption that with the suc-
cess of fetal tissue transplantation, if any, the need for fetal 
tissue as a "curative" will be supplanted to that of a "thera-
py". 121 This could also lead to an astronomical leap in the 
amount of fetal tissue required per year. As Michael Schrage 
put it, "Fetal transplant surgery could become more prevalent 
than heart surgery."122 With this increased demand (with 
over 500,000 Parkinson's patients;123 750,000 diabetics;124 
and 2,000,000 or more Alzheimer patients 125 the potential is 
great) could come the increased pressure from families de-
manding to provide tissue for their ailing family members. 126 
With the ease in obtaining a first-trimester abortion, the possi-
bility of allowing families to conceive in order to abort and 
donate tissue to a family member is real. 127 Although propo-
nents say they could "regulate" so as to avoid this possibility, 
the inconsistency of forbidding directed donations of fetal tis-
sue, when directed donations of other body parts is allowed, is 
already being challenged. 128 
Assuming that a fetus is indeed a life, using fetal trans-
plantation as a therapy would mean that instead of a "life for a 
118 Sheryl Stolberg, Funding Science-For a Pnce; As Public Money Dnes Up, 
Medical Researchers Must Turn to Industry for Help. Private Backing Creates Some 
Controverstal Partnerships, Raises Fears of Commercialism. Conflict of Interest, L.A. 
TIMES, June 8, 1993, at Al. 
119 Id. 
120 Id. 






127 Transplant from Baby for Teen Sister Goes Well, CHI. TRIB., June 5, 1991, 
at ClO (relating the case of a couple's deliberate conception of a child for the pos-
sible use of it as a bone marrow donor (if the blood type was compatible) for their 
older daughter). 
128 Schrage, supra note 74. 
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life" type justification doctors would be dealing with a "life for a 
more comfortable life." When should the quality of one life be 
considered superior to the life of another in and of itself? 
Where would the "killing" stop? Quality of life arguments tend 
to eventually lead to a euthanasia argument. Are we, as a 
society, prepared for that kind of mentality to predominate in 
the medical profession? 
G. Plausible Alternatives 
There are some who believe all the agonizing over the 
elective abortion issue is unnecessary; that the combination of 
alternate research areas and fetal tissue research (limited to 
spontaneously aborted or ectopic fetuses) gives adequate cover-
age to the research into the treatment of PD. Robert H. Baker, 
of Vienna, cites the studies at the University of Toronto and 
Hahnemann University in Philadelphia as examples of alter-
nate areas of research. 129 Both universities "have had signifi-
cantly positive results (in PD patients) from using a substance 
derived from mammalian brain cells to stem damage and 
stimulate brain cell repair in humans." 130 Baker said this line 
of research is "at least as promising as using human fetal 
tissue."131 
Dr. Robert J. White, after reviewing the minimal improve-
ment of Parkinson's patients treated with fetal tissue trans-
plants, urges the use of biotechnological genetic engineering 
(cell lines for one) to treat neurological disease without the use 
of fetal tissue. 132 Recent developments in genetic engineering 
have allowed scientists to "grow fetal brain cells in the lab" and 
insert "genes into the cells to make all sorts of growth-stimulat-
ing chemicals" which, according to Dr. Eugene Major of the 
National Institute of Neurological Disorders and Stroke, "will 
make it unnecessary to use tissue from aborted fetuses." 133 
Joseph Rogers, of the Sun Health Institute for 
Biogerontology Research Center, "is trying to trick brain cells 
from recently deceased adults into believing they are fetus-
129 Robert H. Baker, We Don't Have to Fight over Fetal Tissue, WASH. POST, 
June 22, 1992, at A16. 
130 ld. 
131 ld. But see Turner, supra note 77. 
132 Robert J. White, On Fetal Tissue; The Myth of a Transplant Cure, N.Y. 
TIMES, Aug. 15, 1992, § 1, at 18. 
133 Tim Friend, Living Secrets of Fetal Tissue, USA TODAY, May 18, 1993, at 
7D. 
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es."134 The process is still a long way from being a reality and 
is extremely complex. Scientists will take these live, dopamine 
producing cells and grow them in a test tube, trick them into 
multiplying as "fetal cells," and then trick them again to stop 
multiplying when there is enough replacement tissue. 135 If 
the cells do not stop multiplying, the transplant would, in ef-
fect, become a "tumor" growing "uncontrollably."136 
There are also researchers focusing on drug therapy for PD 
patients. None have yet "alter[ed] the underlying disease pro-
cess," as Dr. Laurence Golbe said, 137 but "some believe it is 
only a matter of time before medication will stop the disease in 
its tracks."138 
One of the newest drugs tested, Deprenyl, has been found 
to delay the need for L-dopa medication for about nine 
months. 139 Since L-dopa medications have a limited useful-
ness, 140"any delay in onset of this treatment is generally con-
sidered a positive step."141 
Dr. Ira Shoulson, of the University of Rochester, says his 
drug research includes "antioxidants that help protect brain 
cells; growth factors that could work at protecting dopamine 
cells; and drugs that block glutamate, a brain chemical thought 
to excite cell death."142 Dr. Shoulson also adds that drug test-
ing has recently begun in conjunction with a cloned gene-a 
dopamine transporter. 143 This phase of testing is "looking for 
drugs that inhibit, or block, the gene," and according to Dr. 
Shoulson, "in animals, it prevents the disorder."144 
There has also been a "resurgence" in two ablative surgical 
procedures, which do not require the use of fetal tissue and 
which originally were used in the 1950s.145 Because of the 
breakthrough in "the theory of the mechanism of brain dys-
1:~4 Lori Baker, Researcher Seeks Parkinson's Cure; "Like Science Fiction" but 
Could Help Many, ARIZ. REPUBLIC, July 28, 1993, at 5. 
135 ld. 
136 ld. 
137 Jamie Talan, Drug for Parkinson's Puts Off Use of Stronger Medication, 
Report Says, NEWSDAY, Jan. 26, 1993, at 61. 
1:18 ld. 
139 ld. 
140 See supra note 15 and accompanying text. 




145 Fazzini, supra note 17, at 1, 4. 
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function underlining Parkinson's Disease," surgeons now are 
retesting these procedures, putting small incisions in "circuitry" 
gone awry due to low dopamine levels. 146 
The pallidotomy (incision in the globus pallidus) is more 
effective in reduction of slow movement problems than in trem-
or reduction, but it does offer an immediate improvement, and 
eventually, a "complete resolution" of the dyskinesia (defect in 
voluntary movement) caused by the drug therapy (actual drug 
requirements remain about the same). 147 Twenty-two 
pallidotomies have been done "without side effects." All the 
pallidotomy subjects have had a fifty-seven percent improve-
ment during the nine months they have been studied. 148 This 
is better than the average of the last two Swedish fetal tissue 
transplantations (at forty-seven and fifty-nine percent improve-
ment).149 Furthermore, fetal transplants do not result in a de-
crease of dyskinesia as does a pallidotomy. 150 
The thalamotomy (an incision in the thalamus) has shown 
a ninety-eight percent reduction of severe tremor and also 
resolves dyskinesia caused by drug therapy. 151 However, it 
also tends to lead to "loss of muscle tone, balance impairment, 
and speech impairment."152 
These alternate sources of treatment materials, with fetus-
es obtained via spontaneous abortion and ectopic pregnancies 
(already argued as sufficient in and of itself), and combined 
with the privately funded, electively aborted fetuses, should be 
sufficient to yield adequate experimental material without 
having to expand the federal funding to electively aborted fe-
tuses. 
H. Fetal Tissue Research Under Clinton 
On November 3, 1992, Bill Clinton was elected President of 
the United States. Within days of his inauguration Clinton did 
what Congress had been unable to do despite months of trying: 
He removed the moratorium on federal funding of research 
involving electively aborted fetuses. 153 
146 !d. at 1. 






153 Talan, supra note 137, at 61. 
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Unfortunately, this action came as no surprise to pro-life, 
anti-abortion supporters. Clinton's political stance on abortion 
during the campaign was pro-choice. 154 Almost immediately 
after his election, Clinton's aides were announcing the probable 
demise of the moratorium.155 Democrats (including Edward 
Kennedy and Richard A. Gephardt) as well as the National 
Abortion Rights Action League (NARAL) expected Clinton to 
honor his promise to free the country from restrictions to a 
woman's right to choose: restrictions on abortions. 156 Kate 
Michelman, president of NARAL, explicitly enumerated the 
things she and the "abortion-rights voters [who] elected" 
Clinton expected him to do: (1) lift the ban on federally funded 
research involving elective abortions; (2) lift the gag rule im-
posed on family planning clinics; (3) lift the ban on RU 486 (the 
abortion pill); (4) codify abortion rights (Freedom of Choice 
Act); and, (5) include abortion in any national health care 
plan.I57 
If Clinton was to avoid Bush's "read my lips" mistake, he 
had to take swift action in this area. On January 22, 1993 
President Clinton did indeed lift the moratorium on federal 
funding of fetal tissue research using elective abortions, 158 
and in May of 1993, a bill authorizing $6 billion in funding to 
the National Institute of Health was passed by both the House 
and Senate. 159 Wanda Franz, President of the National Right 
to Life Committee, said recently that with this the President 
has put "the federal govemment in the business of promoting 
the use of abortion as birth control."160 
V. CONCLUSION 
It is unrealistic to think that "potential good" associated 
with fetal tissue research will not sway abortion decisions. 
Nearly every fetal tissue article written mentions this aspect, 
so persuasion is within the realm of possible ramifications. 
154 Robert S. Boyd, Abortion Restrictions Out; Clinton Keeps Promise, TIMES-
PICAYUNE, Jan. 23, 199::l, at Al. 
155 Elizabeth Neuffer, Bill Vetoed by Bush Could Serve as Clinton's Blueprint, 
BOSTON GLOBE, Nov. 5, 1992, at 27. 
156 !d. 
157 !d. 
158 Boyd, supra note 154. 
159 Fetal Tissue: House Approves NIH Authorization Bill, Abortion Report, 
May 26, 1993. 
160 Boyd, supra note 154. 
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Although I am decidely pro-life, thorough thought and research 
were required for me to decide that using electively aborted 
fetal tissue-even to save loved ones some anguish-was 
wrong. If I can question, so can those who find themselves in 
the uncomfortable position of being undesireably pregnant, 
since they also have a strong reason to rationalize their deci-
sion to abort. 
Limiting the psuedopodic-spread of aborted fetal tissue 
research, and regulating its commercialization once allowed, 
could prove a formidable task, especially as awareness of the 
potential value of fetal tissue spreads. Combining the power to 
persuade, and the potential of regulatory problems with the in-
consistent results of present fetal transplant testing, leads to 
the conclusion that failure to limit use in this area of research 
can only be looked upon as the science fiction movie monster 
turned loose-bent on the destruction (however insidiously) of 
the morals of the American people. 
Billye D. Baird 
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APPENDIX 
Executive Order 12,806 
Establishment of a FETAL TISSUE Bank 
May 19, 1992 
195 
By the authority vested in me as President by the Consti-
tution and the laws of the United States of America, and in 
order to provide a source of human tissue to develop treat-
ments and research methods for various diseases, it is hereby 
ordered as follows: 
Section 1. Establishment of a FETAL TISSUE Bank. The 
Secretary of Health and Human Services ("Secretary") shall 
establish a human FETAL TISSUE bank. The FETAL TISSUE 
in the bank shall be obtained exclusively from ectopic pregnan-
cies and spontaneous abortions. 
Section 2. Procedures. The Secretary shall establish proce-
dures for making tissue from the bank available for meritorious 
research projects selected through an appropriate peer review 
process. The Secretary shall include in the bank a registry of 
physicians and hospitals interested in using the tissue from the 
bank to further specific medical objectives. 
Section 3. Policies. The Secretary shall develop human 
fetal cell lines in a manner consistent with current policy and 
ensure that the actions directed by sections 2 and 3 of this 
order are carried out in accordance with all other applicable 
legal requirements related to FETAL TISSUE. 
Section 4. Report. The Secretary shall report his progress 
in carrying out this order to the President on or before Decem-
ber 31, 1992. 
GEORGE BUSH 
THE WHITE HOUSE, 
May 19, 1992 
Exec. Order No. 12,806, 57 FR 21589, 1992 WL 193236 (Pres.) 
